# OnCo record homologous-recombination-repair (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/homologous-recombination-repair/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "homologous-recombination-repair" ;
  schema:name "Double-strand break repair: HR versus end joining"@en ;
  schema:description "A break through both strands of DNA is the most dangerous lesion a cell faces. Two crews compete to fix it: homologous recombination copies the answer from the sister chromosome (accurate, needs BRCA), while end joining simply glues the ends (fast, sloppy). Which crew wins decides whether PARP inhibitors and radiation kill the cell."@en ;
  schema:url <https://onco.cc/pathways/homologous-recombination-repair/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Homologous_recombination> ;
  schema:citation <https://doi.org/10.1038/nrm.2017.48>, <https://doi.org/10.1126/science.aam7344> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/synthetic-lethality-approaches/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/atr/>, <https://onco.cc/targets/wee1/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:pathways <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/replication-stress/>, <https://onco.cc/pathways/base-excision-repair-parp/>, <https://onco.cc/pathways/synthetic-lethality-map/>, <https://onco.cc/pathways/cgas-sting/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/hereditary-cancer-syndromes/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-lord-science/>, <https://onco.cc/key-papers/paper-chang-nat-rev-mol-cell-biol/> .